By Ben Comer, Chief Editor, Life Science Leader
"You aren’t in control of what the acquisition offers are, but you are in control of whether you take them or not. And if you don’t take them, you better be able to demonstrate value.”
Biohaven Chairman and CEO Vlad Coric’s singular focus on maximizing the value of the company he’s led since 2015 paid off last year, by way of a $11.6 billion Pfizer buyout, the second largest biopharma acquisition in 2022 (just behind Amgen’s $18 billion purchase of Horizon Therapeutics). Instead of resting on his laurels (or joining Pfizer), however, Coric negotiated a second life for Biohaven, focused on developing a new slate of product candidates for neurological and neuropsychiatric diseases.